Antitope

 
Antitope Announces Composite Protein Research Agreement with Cambridge Antibody Technology
24th April 2007 Antitope Ltd., announced a research agreement with the Cambridge Antibody Technology (CAT) for the generation of novel biologics for the potential treatment of cancer.  As part of the agreement, Antitope will apply its proprietary Composite ProteinTM and EpiScreenTM technologies with the aim of developing a therapeutic protein with a reduced risk of immunogenicity.

"We are delighted to be expanding our relationship with CAT" said Dr Matthew Baker, Chief Scientific Officer and founder of Antitope Limited.  "This collaboration provides an opportunity for Antitope to use its expertise in engineering therapeutic proteins to reduce immunogenicity and assist CAT in the development of a therapy that has the potential to treat a range of cancers."

About Antitope

Antitope Ltd. is a Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins to reduce immunogenicity.  Antitope's proprietary Composite ProteinTM technology builds upon the previous pioneering work of its founders in the detection and removal of T cell epitopes in proteins through humanization and de-immunisation technologies.  Antitope are a privately-held company and have established multiple commercial relationships with leading biotechnology and pharmaceutical companies.  For further information on Antitope visit http://www.antitope.co.uk/.

About Cambridge Antibody Technology

  • Cambridge Antibody Technology (CAT) is a biopharmaceutical company using its capabilities and technologies in the discovery and development of new and innovative antibody medicines in selected therapeutic areas to bring improvements to seriously ill patients' lives.
  • CAT is a leader in the discovery and development of human therapeutic antibodies and has an advanced proprietary platform technology for rapidly isolating human monoclonal antibodies using phage display and ribosome display systems. CAT has extensive phage antibody libraries, currently incorporating more than 100 billion distinct antibodies. These libraries form the basis for the Company's strategy to develop a portfolio of antibody-based drugs.
  • CAT is part of the AstraZeneca group of companies.
  • CAT employs over 300 people and is based near Cambridge, UK and in Palo Alto, USA.
  • For more information: www.cambridgeantibody.com

For further information contact:

Dr Neil Butt

Business Development Director

Tel: +44 (0)1223 496190

Email: neil.butt@antitope.co.uk

 


Copyright © 2007 Antitope Ltd. All rights reserved.